Printer Friendly

ROBERTS PHARMACEUTICAL ANNOUNCES SECOND QUARTER RESULTS

 ROBERTS PHARMACEUTICAL ANNOUNCES SECOND QUARTER RESULTS
 EATONTOWN, N.J., Aug. 19 /PRNewswire/ -- Roberts Pharmaceutical


Corporation (NASDAQ: RPCX) today reported total revenues of $8.1 million for the quarter ended June 30, 1992, an increase of $4.5 million or 125 percent over total revenues of $3.6 million for the same quarter of the prior year. Product sales accounted for $5.7 million compared to $2.7 million in 1991. Other operating revenue for the second quarter of 1992 amounted to $1.4 million. Sales of prescription products represented 84 percent of total product sales in 1992. For the six month period ended June 30, 1992, revenues totalled $13.3 million representing an increase of $7.8 million or 142 percent over the prior year period revenues of $5.5 million. Sales of prescription products amounted to $8.2 million, an increase of $5.4 million over the same six month period of the prior year.
 For the second quarter Roberts reported a net loss of $3.6 million or $.25 per share on 14.6 million shares outstanding compared to a net loss for the second quarter of 1991 of $1.0 million or $.12 per share on 8.0 million shares outstanding. The net loss for the six months ended June 30, 1992 was $4.7 million compared to the net loss of $2.6 million for the six months ended June 30, 1991. Loss per share increased $.04 from $.33 for the first six months in 1991 to $.37 for the same period this year.
 The company's operating expenses of $11.3 million for the quarter ended June 30, 1992 were $7.1 million above the $4.2 million incurred during the comparable period in 1991 due largely to increased general and administrative expenses, marketing and R & D costs associated with expanded programs in all three areas.
 In reviewing the results of operations for the second quarter of 1992 compared to the first quarter of 1992, the following overview was presented:
 -- Revenue increased by $2.8 million or 54 percent for the quarter with pharmaceutical product sales accounting for almost one-half of the increase.
 -- Operating expenses increased from $5.9 million to $11.3 million, a $5.4 million increase or 91 percent.
 -- Net loss for the quarter increased by $2.5 million or $.15 per share from $1.1 million or $.10 per share to $3.6 million or $.25 per share.
 -- The primary contributors to the increased loss included:
 Assimilation and organizational refocusing costs related to
 the Hauck and NCRC company acquisitions. $1,000,000
 Non-cash charges related to foreign
 currency exchange. 800,000
 Expanded and accelerated development programs
 for MAXIVENT, AGRELIN, SOMAGARD and AMATINE. 700,000
 Enhanced marketing programs with significant
 increases in field force personnel in support
 of the increased sales base. 400,000
 Total $2,900,000
 Commenting on the results, Dr. Robert A. Vukovich, chairman and CEO, said, "The revenue levels achieved for both the current three month period and year to date demonstrate Roberts continued growth and expansion. We have integrated the operations of our latest corporate acquisitions, W.E. Hauck and NCRC and continue to strengthen our relationship with the Yamanouchi Pharmaceutical Co., Ltd. of Japan. We continue to look toward our goal of achieving profitability while concentrating our efforts on the near-term launch of SUPPRELIN, the continued support of our AMATINE program, and the increased development activities of MAXIVENT, AGRELIN and SOMAGARD, as these products move closer toward FDA review."
 ROBERTS PHARMACEUTICAL CORPORATION
 Summary Consolidated Financial Information
 (Unaudited -- In thousands, except per share data)
 Balance Sheet Data 6/30/92 12/31/91
 Assets
 Cash and marketable securities $ 93,860 $ 14,161
 Other current assets 10,272 5,600
 Other assets 45,270 24,389
 Total assets 149,402 44,150
 Liabilities & Stockholders' Equity
 Current liabilities 13,648 9,807
 Long-term debt and other liabilities 10,579 9,237
 Stockholders' equity 125,175 25,106
 Total liabilities & stockholders' equity 149,402 44,150
 Operating Statement Data
 Periods Ended Three months Six months
 June 30 1992 1991 1992 1991
 Revenues:
 Product sales $5,728 $2,745 $10,273 $4,126
 Other revenue
 including
 interest 2,350 888 3,047 1,337
 Total 8,078 3,633 13,320 5,463
 Net loss (3,595) (982) (4,689) (2,576)
 Net loss per common share (.25) (.12) (.37) (.33)
 Weighted average common
 shares outstanding 14,569 7,968 12,706 7,851
 -0- 8/19/92
 /CONTACT: Anthony P. Maris of Roberts Pharmaceuticals, 908-389-1182/
 (RPCX) CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU: ERN


PS-OS -- NY053 -- 1438 08/19/92 15:38 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 19, 1992
Words:775
Previous Article:CHRYSLER TO HOLD ITS FIRST WORLDWIDE DEALER PREVIEW
Next Article:MOODY'S ASSIGNS 'Aa3' RATING TO GREAT LAKES HIGHER EDUCATION CORPORATION
Topics:


Related Articles
ROBERTS PHARMACEUTICALS ANNOUNCES THIRD QUARTER RESULTS
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES THIRD QUARTER RESULTS
ROBERTS PHARMACEUTICAL CORPORATION REPORTS RECORD 1992 SALES RESULTS
ROBERTS PHARMACEUTICAL CORPORATION REPORTS RECORD SALES AND PROFITS
ROBERTS PHARMACEUTICAL CORPORATION REPORTS FIFTH STRAIGHT QUARTER OF PROFITABLE EARNINGS
ROBERTS PHARMACEUTICAL CLARIFIES PREVIOUSLY ANNOUNCED 1994 FINANCIAL RESULTS
ROBERTS COMMENTS ON PRELIMINARY RESULTS FOR FIRST TWO MONTHS OF SECOND QUARTER
ROBERTS PHARMACEUTICAL CORPORATION REPORTS RECORD SECOND QUARTER REVENUES
Roberts Pharmaceutical Corporation Reports Second Quarter Results Substantially Improved From First Quarter 1996 Results
Roberts Pharmaceutical Corporation Reports Strong Second-Quarter Results With Per Share Earnings Exceeding Analyst Estimates

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters